{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:07:23Z","timestamp":1794049643880,"version":"4.8.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cannabis use disorder (CUD) is increasingly common and contributes to a range of health and social problems. Cannabidiol (CBD) is a non-intoxicating cannabinoid recognised for its anticonvulsant, anxiolytic and antipsychotic effects with no habit-forming qualities. Results from a Phase IIa randomised clinical trial suggest that treatment with CBD for four weeks reduced non-prescribed cannabis use in people with CUD. This study examines the efficacy, safety and quality of life of longer-term CBD treatment for patients with moderate-to-severe CUD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/Design<\/jats:title>\n                <jats:p>A phase III multi-site, randomised, double-blinded, placebo controlled parallel design of a 12-week course of CBD to placebo, with follow-up at 24\u00a0weeks after enrolment.<\/jats:p>\n                <jats:p>Two hundred and fifty adults with moderate-to-severe CUD (target 20% Aboriginal), with no significant medical, psychiatric or other substance use disorders from seven drug and alcohol clinics across NSW and VIC, Australia will be enrolled.<\/jats:p>\n                <jats:p>Participants will be administered a daily dose of either 4\u00a0mL (100\u00a0mg\/mL) of CBD or a placebo dispensed every 3-weeks. All participants will receive four-sessions of Cognitive Behavioural Therapy (CBT) based counselling. Primary endpoints are self-reported cannabis use days and analysis of cannabis metabolites in urine. Secondary endpoints include severity of CUD, withdrawal severity, cravings, quantity of use, motivation to stop and abstinence, medication safety, quality of life, physical\/mental health, cognitive functioning, and patient treatment satisfaction. Qualitative research interviews will be conducted with Aboriginal participants to explore their perspectives on treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Current psychosocial and behavioural treatments for CUD indicate that over 80% of patients relapse within 1\u20136\u00a0months of treatment. Pharmacological treatments are highly effective with other substance use disorders but there are no approved pharmacological treatments for CUD. CBD is a promising candidate for CUD treatment due to its potential efficacy for this indication and excellent safety profile. The anxiolytic, antipsychotic and neuroprotective effects of CBD may have added benefits by reducing many of the mental health and cognitive impairments reported in people with regular cannabis use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Australian and New Zealand Clinical Trial Registry: ACTRN12623000526673 (Registered 19 May 2023).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-024-05616-3","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T04:10:12Z","timestamp":1709525412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol"],"prefix":"10.1186","volume":"24","author":[{"given":"Anjali K.","family":"Bhardwaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llew","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshman","family":"Sahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Montebello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Monds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Arunogiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Lorenzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan I.","family":"Lubman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Malouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Harrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"5616_CR1","unstructured":"UNODC: World Drug Report. In.; 2022."},{"key":"5616_CR2","unstructured":"AIHW: Alcohol, tobacco & other drugs in Australia. In. Canberra: Commonwealth of Australia: Australian Institute of Health and Welfare; 2023."},{"issue":"12","key":"5616_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"L Degenhardt","year":"2018","unstructured":"Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, Whiteford H, Leung J, Naghavi M, Griswold M, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987\u20131012.","journal-title":"Lancet Psychiatry"},{"key":"5616_CR4","volume-title":"The health and social effects of nonmedical cannabis use","author":"WHO","year":"2016","unstructured":"WHO. The health and social effects of nonmedical cannabis use. Geneva: World Health Organisation; 2016."},{"issue":"12","key":"5616_CR5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0004867412460591","volume":"46","author":"M Teesson","year":"2012","unstructured":"Teesson M, Slade T, Swift W, Mills K, Memedovic S, Mewton L, Grove R, Newton N, Hall W. Prevalence, correlates and comorbidity of DSM-IV Cannabis Use and Cannabis Use Disorders in Australia. Aust N Z J Psychiatry. 2012;46(12):1182\u201392.","journal-title":"Aust N Z J Psychiatry"},{"issue":"56","key":"5616_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19560","volume":"19","author":"K Cooper","year":"2015","unstructured":"Cooper K, Chatters R, Kaltenthaler E, Wong R. Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Health Technol Assess. 2015;19(56):1\u2013130.","journal-title":"Health Technol Assess"},{"issue":"7","key":"5616_CR7","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/add.15743","volume":"117","author":"JP Connor","year":"2022","unstructured":"Connor JP, Stjepanovic D, Budney AJ, Le Foll B, Hall WD. Clinical management of cannabis withdrawal. Addiction. 2022;117(7):2075\u201395.","journal-title":"Addiction"},{"issue":"5","key":"5616_CR8","first-page":"CD005336","volume":"2016","author":"PJ Gates","year":"2016","unstructured":"Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev. 2016;2016(5):CD005336.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"5616_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","volume":"71","author":"DJ Allsop","year":"2014","unstructured":"Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, Holland RM, Muhleisen P, Norberg MM, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiat. 2014;71(3):281\u201391.","journal-title":"JAMA Psychiat"},{"issue":"4","key":"5616_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1037\/1064-1297.6.4.419","volume":"6","author":"A Budney","year":"1998","unstructured":"Budney A, Radonovich K, Higgins S, Wong C. Adults seeking treatment for Marijuana dependence: a comparsion with cocaine-dependent treatment seekers. Exp Clin Psychopharmacol. 1998;6(4):419\u201326.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"2","key":"5616_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/09540260902782745","volume":"21","author":"J Copeland","year":"2009","unstructured":"Copeland J, Swift W. Cannabis use disorder: epidemiology and management. Int Rev Psychiatry. 2009;21(2):96\u2013103.","journal-title":"Int Rev Psychiatry"},{"issue":"2","key":"5616_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.psc.2012.03.003","volume":"35","author":"I Danovitch","year":"2012","unstructured":"Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. Psychiatr Clin North Am. 2012;35(2):309\u201326.","journal-title":"Psychiatr Clin North Am"},{"issue":"6","key":"5616_CR13","doi-asserted-by":"publisher","first-page":"e208279","DOI":"10.1001\/jamanetworkopen.2020.8279","volume":"3","author":"LA Ray","year":"2020","unstructured":"Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(6):e208279.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"5616_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/npp.2017.212","volume":"43","author":"CA Brezing","year":"2018","unstructured":"Brezing CA, Levin FR. The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology. 2018;43(1):173\u201394.","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"5616_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M19-1105","volume":"172","author":"KK Kondo","year":"2020","unstructured":"Kondo KK, Morasco BJ, Nugent SM, Ayers CK, O\u2019Neil ME, Freeman M, Kansagara D. Pharmacotherapy for the treatment of cannabis use disorder: a systematic review. Ann Intern Med. 2020;172(6):398\u2013412.","journal-title":"Ann Intern Med"},{"issue":"9","key":"5616_CR16","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamainternmed.2019.1993","volume":"179","author":"N Lintzeris","year":"2019","unstructured":"Lintzeris N, Bhardwaj A, Mills L, Dunlop A, Copeland J, McGregor I, Bruno R, Gugusheff J, Phung N, Montebello M, et al. Nabiximols for the treatment of cannabis dependence: a randomized clinical trial. JAMA Intern Med. 2019;179(9):1242\u201353.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"5616_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/cpt.109","volume":"97","author":"DJ Allsop","year":"2015","unstructured":"Allsop DJ, Lintzeris N, Copeland J, Dunlop A, McGregor IS. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal. Clin Pharmacol Ther. 2015;97(6):571\u20134.","journal-title":"Clin Pharmacol Ther"},{"key":"5616_CR18","unstructured":"Publication of interim decisions proposing to amend, or not amend, the current Poisons Standard, September 2018 [https:\/\/www.tga.gov.au\/resources\/publication\/scheduling-decisions-interim\/publication-interim-decisions-amending-or-not-amending-current-poisons-standard-february-2019\/11-nabiximols]."},{"issue":"1","key":"5616_CR19","first-page":"1","volume":"22","author":"A Arzimanoglou","year":"2020","unstructured":"Arzimanoglou A, Brandl U, Cross JH, Gil-Nagel A, Lagae L, Landmark CJ, Specchio N, Nabbout R, Thiele EA, Gubbay O, et al. Epilepsy and cannabidiol: a guide to treatment. Epileptic Disord. 2020;22(1):1\u201314.","journal-title":"Epileptic Disord"},{"key":"5616_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","volume":"74","author":"S Bonaccorso","year":"2019","unstructured":"Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology. 2019;74:282\u201398.","journal-title":"Neurotoxicology"},{"issue":"3","key":"5616_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225\u201331.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"5616_CR22","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1111\/bcp.14038","volume":"85","author":"SA Millar","year":"2019","unstructured":"Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O\u2019Sullivan SE. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol. 2019;85(9):1888\u2013900.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"5616_CR23","doi-asserted-by":"publisher","first-page":"bjgpopen20X1010","DOI":"10.3399\/bjgpopen20X101010","volume":"4","author":"G Gulbransen","year":"2020","unstructured":"Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020;4(1):bjgpopen20X101010.","journal-title":"BJGP Open"},{"key":"5616_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.neubiorev.2016.11.012","volume":"72","author":"AL Osborne","year":"2017","unstructured":"Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev. 2017;72:310\u201324.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"5616_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41386-019-0518-1","volume":"45","author":"S Elsaid","year":"2020","unstructured":"Elsaid S, Le Foll B. The complexity of pharmacology of cannabidiol (CBD) and its implications in the treatment of brain disorders. Neuropsychopharmacology. 2020;45(1):229\u201330.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"5616_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","volume":"172","author":"JM McPartland","year":"2015","unstructured":"McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172(3):737\u201353.","journal-title":"Br J Pharmacol"},{"key":"5616_CR27","unstructured":"Publication of interim decisions proposing to amend, or not amend, the current Poisons Standard, September 2018 [https:\/\/www.tga.gov.au\/book-page\/15-cannabidiol-and-tetrahydrocannabinols-thcs]."},{"issue":"Pt A","key":"5616_CR28","doi-asserted-by":"publisher","first-page":"106938","DOI":"10.1016\/j.yebeh.2020.106938","volume":"104","author":"L Taylor","year":"2020","unstructured":"Taylor L, Crockett J, Tayo B, Checketts D, Sommerville K. Abrupt withdrawal of cannabidiol (CBD): a randomized trial. Epilepsy Behav. 2020;104(Pt A):106938.","journal-title":"Epilepsy Behav"},{"issue":"11","key":"5616_CR29","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","volume":"45","author":"E Chesney","year":"2020","unstructured":"Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, Freeman TP, McGuire P. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020;45(11):1799\u2013806.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"5616_CR30","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"CJ Lucas","year":"2018","unstructured":"Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477\u201382.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"5616_CR31","doi-asserted-by":"publisher","first-page":"8384","DOI":"10.1073\/pnas.122149199","volume":"99","author":"D Robbe","year":"2002","unstructured":"Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A. 2002;99(12):8384\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"5616_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0306-4522(96)00428-9","volume":"77","author":"M Glass","year":"1997","unstructured":"Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77(2):299\u2013318.","journal-title":"Neuroscience"},{"key":"5616_CR33","unstructured":"Epidyolex (Cannabidiol). In. Edited by Pharmaceuticals J. Kent, UK: Jazz Pharmaceuticals; 2024."},{"key":"5616_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fpsyt.2019.00063","volume":"10","author":"Y Chye","year":"2019","unstructured":"Chye Y, Christensen E, Solowij N, Yucel M. The endocannabinoid system and cannabidiol\u2019s promise for the treatment of substance use disorder. Front Psychiatry. 2019;10:63.","journal-title":"Front Psychiatry"},{"issue":"11","key":"5616_CR35","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, Oprescu AM, Salsitz E. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019;176(11):911\u201322.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"5616_CR36","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","volume":"38","author":"CJ Morgan","year":"2013","unstructured":"Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013;38(9):2433\u20136.","journal-title":"Addict Behav"},{"issue":"12","key":"5616_CR37","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995\u20131010.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"5616_CR38","doi-asserted-by":"publisher","first-page":"e12762","DOI":"10.1111\/adb.12762","volume":"25","author":"C Hindocha","year":"2020","unstructured":"Hindocha C, Freeman TP, Schafer G, Gardner C, Bloomfield MAP, Bramon E, Morgan CJA, Curran HV. Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the CB1 receptor and FAAH enzyme. Addict Biol. 2020;25(3):e12762.","journal-title":"Addict Biol"},{"issue":"3","key":"5616_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2217\/fnl-2016-0035","volume":"12","author":"I Pokorski","year":"2017","unstructured":"Pokorski I, Clement N, Phung N, Weltman M, Fu S, Copeland J. Cannabidiol in the management of inpatient cannabis withdrawal: clinical case series. Future Neurol. 2017;12(3):133\u201340.","journal-title":"Future Neurol"},{"issue":"7","key":"5616_CR40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.biopsych.2015.12.002","volume":"79","author":"SJ Broyd","year":"2016","unstructured":"Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol Psychiatry. 2016;79(7):557\u201367.","journal-title":"Biol Psychiatry"},{"key":"5616_CR41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","volume":"107","author":"AM Freeman","year":"2019","unstructured":"Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, Saunders R, Freeman TP. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev. 2019;107:696\u2013712.","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"5616_CR42","first-page":"31","volume":"14","author":"S Shannon","year":"2015","unstructured":"Shannon S, Opila-Lehman J. Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integr Med Clin J. 2015;14(6):31\u20135.","journal-title":"Integr Med Clin J"},{"issue":"2","key":"5616_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/jcpt.12018","volume":"38","author":"JA Crippa","year":"2013","unstructured":"Crippa JA, Hallak JE, Machado-de-Sousa JP, Queiroz RH, Bergamaschi M, Chagas MH, Zuardi AW. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther. 2013;38(2):162\u20134.","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"5616_CR44","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, Freeman AM, Lees R, Craft S, Morrison PD, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020;7(10):865\u201374.","journal-title":"Lancet Psychiatry"},{"key":"5616_CR45","doi-asserted-by":"publisher","first-page":"899221","DOI":"10.3389\/fpsyt.2022.899221","volume":"13","author":"G Cleirec","year":"2022","unstructured":"Cleirec G, Desmier E, Lacatus C, Lesgourgues S, Braun A, Peloso C, Obadia C. Efficiency of inhaled cannabidiol in cannabis use disorder: the pilot study cannavap. Front Psychiatry. 2022;13:899221.","journal-title":"Front Psychiatry"},{"key":"5616_CR46","doi-asserted-by":"publisher","first-page":"829944","DOI":"10.3389\/fpsyt.2022.829944","volume":"13","author":"D Fortin","year":"2022","unstructured":"Fortin D, Di Beo V, Massin S, Bisiou Y, Carrieri P, Barre T. A \u201cGood\u201d Smoke? The off-label use of cannabidiol to reduce cannabis use. Front Psychiatry. 2022;13:829944.","journal-title":"Front Psychiatry"},{"issue":"1","key":"5616_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/can.2017.0043","volume":"3","author":"N Solowij","year":"2018","unstructured":"Solowij N, Broyd SJ, Beale C, Prick JA, Greenwood LM, van Hell H, Suo C, Galettis P, Pai N, Fu S, et al. Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res. 2018;3(1):21\u201334.","journal-title":"Cannabis Cannabinoid Res"},{"key":"5616_CR48","doi-asserted-by":"crossref","unstructured":"Lorenzetti V, McTavish E, Broyd S, van Hell H, Ganella E, Kottaram AR, Beale C, Martin J, Galettis P, Solowij N et al. Daily cannabidiol administration for 10 weeks modulates hippocampal and amygdalar resting-state functional connectivity in cannabis users: a functional magnetic resonance imaging open-label clinical trial. Cannabis Cannabinoid Res. 2023.","DOI":"10.1089\/can.2022.0336"},{"issue":"2","key":"5616_CR49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00213-022-06303-5","volume":"240","author":"R Lees","year":"2023","unstructured":"Lees R, Hines LA, Hindocha C, Baio G, Shaban NDC, Stothart G, Mofeez A, Morgan CJA, Curran HV, Freeman TP. Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder. Psychopharmacology. 2023;240(2):337\u201346.","journal-title":"Psychopharmacology"},{"key":"5616_CR50","doi-asserted-by":"publisher","first-page":"107993","DOI":"10.1016\/j.drugalcdep.2020.107993","volume":"212","author":"MJE Loflin","year":"2020","unstructured":"Loflin MJE, Kiluk BD, Huestis MA, Aklin WM, Budney AJ, Carroll KM, D\u2019Souza DC, Dworkin RH, Gray KM, Hasin DS, et al. The state of clinical outcome assessments for cannabis use disorder clinical trials: a review and research agenda. Drug Alcohol Depend. 2020;212:107993.","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20132","key":"5616_CR51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.drugalcdep.2011.06.003","volume":"119","author":"DJ Allsop","year":"2011","unstructured":"Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011;119(1\u20132):123\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"5616_CR52","first-page":"22","volume":"59 Suppl 20","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22\u201333 quiz 34-57.","journal-title":"J Clin Psychiatry."},{"key":"5616_CR53","unstructured":"AIHW: Alcohol and other drug treatment services in Australia annual report - 2019. In. Canberra: Commonwealth of Australia: Australian Institue of Health and Welfare; 2020."},{"key":"5616_CR54","unstructured":"Whetton S, Trait R, J, Chrzanowska A, Donnelly N, McEntee A, Mukhtar A, Zahra E, Campbell G, Degenhardt L, Dey T et al. Quantifying the Social Costs of Cannabis Use to Australia in 2015\/16. In. Perth, WA: National Drug Research Institute, Curtin University; 2020."},{"issue":"5","key":"5616_CR55","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1037\/a0015808","volume":"40","author":"CJ Ferguson","year":"2009","unstructured":"Ferguson CJ. An effect size primer: a guide for clinicians and researchers. Prof Psychol Res Pract. 2009;40(5):532\u20138.","journal-title":"Prof Psychol Res Pract"},{"key":"5616_CR56","volume-title":"Counselling Guidelines: Alcohol and other drug issues","author":"J Stone","year":"2019","unstructured":"Stone J, Marsh A, Dale A, Willis L, O\u2019Toole S, Helfgott S, Bennetts A, Cleary L, Ditchburn S, Jacobson H, et al. Counselling Guidelines: Alcohol and other drug issues. Mental Health Commission: Perth; 2019."},{"issue":"2","key":"5616_CR57","first-page":"163","volume":"17","author":"P Sabioni","year":"2019","unstructured":"Sabioni P, Le Foll B. Psychosocial and pharmacological interventions for the treatment of cannabis use disorder. Focus (Am Psychiatr Publ). 2019;17(2):163\u20138.","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"11","key":"5616_CR58","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, Amtmann D, Bode R, Buysse D, Choi S, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008. J Clin Epidemiol. 2010;63(11):1179\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"5616_CR59","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/jme.2004.009290","volume":"31","author":"CL Fry","year":"2005","unstructured":"Fry CL, Ritter A, Baldwin S, Bowen KJ, Gardiner P, Holt T, Jenkinson R, Johnston J. Paying research participants: a study of current practices in Australia. J Med Ethics. 2005;31(9):542\u20137.","journal-title":"J Med Ethics"},{"issue":"1","key":"5616_CR60","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5204\/ijcis.v3i1.57","volume":"3","author":"D Bessarab","year":"2010","unstructured":"Bessarab D, Ng\u2019Andu B. Yarning about yarning as a legitimate method in Indigenous research. Int J Crit Indig Stud. 2010;3(1):37\u201350.","journal-title":"Int J Crit Indig Stud"},{"key":"5616_CR61","first-page":"530","volume-title":"Front Matter","author":"JK Kruschke","year":"2015","unstructured":"Kruschke JK. Doing Bayesian Data Analysis: A tutorial with R, JAGS, and Stan. In: Inc E, editor. Front Matter. 2nd ed. Bloomington: Indiana University; 2015. p. 530\u201350.","edition":"2"},{"key":"5616_CR62","doi-asserted-by":"crossref","unstructured":"van Buuren S: Flexible imputation of missing data. Stef Van Buuren. , 2 edn: Chapman & Hall Books; 2018.","DOI":"10.1201\/9780429492259"},{"issue":"1","key":"5616_CR63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/BF00988593","volume":"13","author":"J Corbin","year":"1990","unstructured":"Corbin J, Strauss A. Grounded theory research: procedures, canons, and evaluative criteria. Qual Sociol. 1990;13(1):3\u201321.","journal-title":"Qual Sociol"},{"issue":"3","key":"5616_CR64","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.drugalcdep.2011.09.007","volume":"121","author":"MM Norberg","year":"2012","unstructured":"Norberg MM, Mackenzie J, Copeland J. Quantifying cannabis use with the timeline followback approach: a psychometric evaluation. Drug Alcohol Depend. 2012;121(3):247\u201352.","journal-title":"Drug Alcohol Depend"},{"key":"5616_CR65","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. In.; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"5616_CR66","doi-asserted-by":"crossref","unstructured":"Heishman S, J, Singleton E, G, Liguori A: Marijuana Craving Questionnaire: Development and initial validation of a self-report instrument. In., vol. 96. Addiction; 2001.","DOI":"10.1037\/t04126-000"},{"issue":"5","key":"5616_CR67","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1037\/0022-006X.68.5.898","volume":"68","author":"RS Stephens","year":"2000","unstructured":"Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol. 2000;68(5):898\u2013908.","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"5616_CR68","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1037\/0022-006X.62.1.92","volume":"62","author":"RS Stephens","year":"1994","unstructured":"Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol. 1994;62(1):92\u20139.","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"5616_CR69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/dar.12083","volume":"33","author":"A Ryan","year":"2014","unstructured":"Ryan A, Holmes J, Hunt V, Dunlop A, Mammen K, Holland R, Sutton Y, Sindhusake D, Rivas G, Lintzeris N. Validation and implementation of the Australian Treatment Outcomes Profile in specialist drug and alcohol settings. Drug Alcohol Rev. 2014;33(1):33\u201342.","journal-title":"Drug Alcohol Rev"},{"issue":"9","key":"5616_CR70","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","volume":"86","author":"TF Heatherton","year":"1991","unstructured":"Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The fagerstrom test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire. Br J Addict. 1991;86(9):1119\u201327.","journal-title":"Br J Addict"},{"issue":"1\u20133","key":"5616_CR71","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.schres.2008.02.020","volume":"103","author":"OJ Mason","year":"2008","unstructured":"Mason OJ, Morgan CJ, Stefanovic A, Curran HV. The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res. 2008;103(1\u20133):138\u201342.","journal-title":"Schizophr Res"},{"key":"5616_CR72","unstructured":"The PTSD Checklist for \u00ad_DSM-5_ (PCL-5). [www.ptsd.va.gov]."},{"key":"5616_CR73","doi-asserted-by":"crossref","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health and Quality of Life Outcomes. 2004;2(12).","DOI":"10.1186\/1477-7525-2-12"},{"issue":"1","key":"5616_CR74","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00213-012-2954-z","volume":"227","author":"ME Morean","year":"2013","unstructured":"Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O\u2019Malley SS. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology. 2013;227(1):177\u201392.","journal-title":"Psychopharmacology"},{"key":"5616_CR75","doi-asserted-by":"crossref","unstructured":"Thurber KA, Colonna E, Jones R, Gee GC, Priest N, Cohen R, Williams DR, Thandrayen J, Calma T, Lovett R et al. Prevalence of everyday discrimination and relation with wellbeing among Aboriginal and Torres Strait Islander adults in Australia. Int J Environ Res Public Health. 2021;18(12).","DOI":"10.3390\/ijerph18126577"},{"issue":"10","key":"5616_CR76","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1080\/09602011.2021.1958874","volume":"32","author":"I van der Linde","year":"2022","unstructured":"van der Linde I, Horsman L, Bright P. The validity of abbreviated forms of the National Adult Reading Test and Spot-the-Word 2 for estimating full-scale IQ. Neuropsychol Rehabil. 2022;32(10):2534\u201343.","journal-title":"Neuropsychol Rehabil"},{"key":"5616_CR77","first-page":"286","volume":"28","author":"A Rey","year":"1941","unstructured":"Rey A. L\u2019examen psychologique dans les cas d\u2019encephopathie traumatique. Archives de Psychologie. 1941;28:286\u2013340.","journal-title":"Archives de Psychologie"},{"issue":"1","key":"5616_CR78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3758\/BF03203267","volume":"16","author":"BA Eriksen","year":"1974","unstructured":"Eriksen BA, Eriksen CW. Effects of noise letters upon the identification of a target letter in a nonsearch task. Perception Psychophysics. 1974;16(1):143\u20139.","journal-title":"Perception Psychophysics"},{"issue":"4","key":"5616_CR79","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1037\/h0043688","volume":"55","author":"WK Kirchner","year":"1958","unstructured":"Kirchner WK. Age differences in short-term retention of rapidly changing information. J Exp Psychol. 1958;55(4):352\u20138.","journal-title":"J Exp Psychol"},{"key":"5616_CR80","doi-asserted-by":"crossref","unstructured":"D W: Wechsler Adult Intelligence Scale - Third Edition (WAIS-III), 3 edn. San Antonio: The Psychological Corporation; 1997.","DOI":"10.1037\/t49755-000"},{"issue":"5","key":"5616_CR81","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1037\/h0044509","volume":"19","author":"RM Reitan","year":"1955","unstructured":"Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol. 1955;19(5):393\u20134.","journal-title":"J Consult Psychol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-05616-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T20:04:53Z","timestamp":1709841893000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-05616-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5616"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-05616-3","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate: Sydney Local Health District Human Research Ethics Committee, Ref: 2022\/ETH02467 on 03 February 2023. The Aboriginal Health and Medical Research Council\u2019s Human Research Ethics Committee, Ref: 2110\/23 on 30 May 2023. The sites: South East Sydney Local Health District, Sydney Local Health District, Northern Sydney Local Health District, Western Sydney Local Health District, Hunter New England Local Health District and Eastern Health, Turning Point will receive site-specific ethics approval.All participants will sign a Participant Information Consent Form (PICF) before being enrolled in the study. Informed consent involves a 3-step process. (1) Verbal information about the trial is provided to the participant either face-to-face or over a telephone during the initial screen. (2) Participants eligible for a medical screen will be asked to sign a \u2018medical screening consent form\u2019 before seeing the study medical officer. (3) If the participant is deemed eligible by the study medical officer and the medical officer\/ site coordinator has verbally discussed the trial to the participant and any queries or concerns addressed, the participant will sign the PICF on day 1 of commencing the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The participant information consent form includes a section relating to consent for de-identified data to be published. This is however not applicable for this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}